文献速递类风湿关节炎脊柱关节炎

美国风湿病学会与美国食品药品监督管理局峰会:2022年5月17-18日会议摘要

American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022.
PubMed 文献 · Arthritis Rheumatol · 2024-05-28

美国风湿病学会与美国食品药品监督管理局于2022年5月共同举办公开会议,讨论类风湿关节炎(RA)和银屑病关节炎(PsA)药物临床开发中的挑战,聚焦创新临床试验设计、结局指标和数据收集方法。建议包括早期剂量范围研究和使用活性对照药,并探讨了利用电子健康记录和索赔数据评估长期安全性、真实世界证据和人工智能在监管评价中的作用。

要点

  • 建议开展早期剂量范围研究并使用活性对照药。
  • 提出在RA中采用非劣效性临床试验设计,以活性对照药评价新药。
  • 强调需要更能反映治疗目标的结局指标,以及先进影像在未来试验中的潜力。

核心结论

  • 会议讨论了RA和PsA药物临床开发中的挑战与机会,涉及试验设计、结局指标和数据收集方法。

研究设计与样本

  • 美国风湿病学会与美国食品药品监督管理局于2022年5月共同举办公开会议,聚焦RA和PsA药物临床开发中的创新临床试验设计、结局指标和数据收集方法。

主要发现

  • 建议包括早期剂量范围研究和使用活性对照药。
  • 讨论了利用电子健康记录和索赔数据评估长期安全性的挑战与机会,以及欧洲登记处的见解和真实世界证据与人工智能在监管评价中不断演变的作用。
  • 探讨了RA和PsA试验中评估疾病活动的终点和结局指标,强调定义缓解、评估临床反应和评价结构进展方面的挑战。
  • 讨论了RA中安慰剂对照试验的挑战,并提出采用非劣效性临床试验设计,以活性对照药评价新药。
  • 强调了RA和PsA中采用去中心化方法的实用性试验的真实世界相关性和行政效率。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The American College of Rheumatology and the US Food and Drug Administration co-sponsored a public meeting in May 2022 about challenges in the clinical development of drugs for rheumatoid arthritis (RA) and psoriatic arthritis (PsA), focusing on innovative clinical trial designs, outcome measures, and data collection methods. Recommendations include early dose-ranging studies and use of active comparators. Challenges and opportunities in assessing long-term safety by leveraging real-world data from electronic health records (EHRs) and claims data are discussed, along with insights from European registries and the evolving role of real-world evidence and artificial intelligence in regulatory evaluations. Endpoints for assessing disease activity and outcome measures used in RA and PsA trials are explored, emphasizing challenges in defining remission, assessing clinical response, and evaluating structural progression. The need for outcome measures that better reflect treatment targets and the potential of advanced imaging in future trials are highlighted. Challenges with placebo-controlled trials in RA are discussed and use of non-inferiority clinical trial design, in which new drugs are evaluated with active comparators, is proposed. Pragmatic trials in RA and PsA, employing decentralized approaches, are highlighted for their real-world relevance and administrative efficiencies. Strategies for identifying at-risk populations for RA and the challenges of using EHRs and insurance claims data in drug development are discussed. Registry data and digital health technologies show promise in bridging the gap between clinical trials and real-world effectiveness.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kay J, Nikolov NP, Weisman MH, et al. American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022. Arthritis Rheumatol. 2024. PMID: 38622107. doi:10.1002/art.42864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。